Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer

Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T–based hybrid imaging. The PSMA-I&T scaffold represents a versatile PSMA-targeted lead structure, allowing relatively straightforward adaptation to the different structural requirements of dedicated nuclear or hybrid imaging agents.

Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Schottelius, M., Wurzer, A., Wissmiller, K., Beck, R., Koch, M., Gorpas, D., Notni, J., Buckle, T., van Oosterom, M. N., Steiger, K., Ntziachristos, V., Schwaiger, M., van Leeuwen, F. W. B., Wester, H.-J. Tags: Basic Source Type: research